KAI1/CD82和E-Cadherin蛋白在卵巢上皮性癌中表达的临床意义

Effect of KAI1/CD82 and E-Cadherin expression in epithelial ovarian carcinoma

目的:探讨肿瘤转移抑制基因KAI1和粘附分子钙粘蛋白基因E-Cadherin的表达与卵巢上皮性癌临床病理因素的相关性。方法:对66例肿瘤标本应用免疫组织化学SP法检测KAI1/CD82和E-Cadherin蛋白在卵巢上皮性癌组织中的表达,生物学统计采用χ2检验法。结果:KAI1/CD82蛋白表达的阳性率为57.58%(38/66);E-Cadherin蛋白阳性率为46.97%(31/66)。两种基因蛋白表达与肿瘤临床分期及淋巴结转移密切相关,差异有统计学意义(P<0.05);KAI1/CD82蛋白的表达与肿瘤的组织学分级呈负相关(P<0.05)。在同一标本中,二者表达有较好的相关性和一致性,差异具有统计学意义(P<0.05)。结论:KAI1/CD82和E-Cadherin蛋白的表达与卵巢上皮性癌的演进和转移密切相关,检测其表达异常对判断肿瘤的分化、临床进展以及推测预后有一定的参考价值。

Objective：To investigate the relationship between epithelial ovarian carcinoma（EOC）and levels of the tumor metastasis suppressor gene KAIl/CD82 and the adhesion molecule E-Cadherin（E-cad）. Methods： Immunohistochemistry SP method was used to examine the expression levels of KAI1 and E-cad in 66 specimens of EOC. Results： Of them, 38 showed positive KAI1/CD82 protein （57.58%） and 31 positive E-cad protein（46. 97%. The statistical evaluation revealed a close relation among the clinical stage, lymph node metastasis and the expressions of KAI1/CD82 and E-cad（ P 〈 0.05）, and an inverse relationship between the histological grade and KAI1/ CD82 expression levels（ P 〈 0.05）, suggesting expressions of KAI1/CD82 and E-cad had great consistency in the same sample. Conclusion：Expressions of KAI1/CD82 and E-cad protein are closely related with the malignant progression and metastasis of EOC, which have important implication for evaluation of the differentiation and tumor progression and prediction of the prognosis in EOC.